Dare Bioscience, Inc. Aktie News

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is nec...

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Fi...

In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probioti...

Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Trading Douglas Tsao - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference...

With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update.

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management

The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health.